Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16341980 | 1.00 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL24522 | 1.00 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL562424 | 0.99 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL21465147 | 0.96 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30001975 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21586620 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL17999158 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL16729899 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL18013131 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL13454616 | 0.88 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | MCCARTHY JAMES R (US) | 2003-06-12 | — | — | US | disclosed |
| US-5977325-A | NUCLEOSIDE DERIVATIVES USEFUL AS ANTICARCINOGENIC/ANTITUMOR AGENTS AND VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5792841-A | ANTIVIRAL, ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5616702-A | ANTITUMOR AGENTS, VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5607925-A | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5378693-A | Antitumor agents or viricides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0372268-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMA (US) | 1994-05-04 | — | — | EP | disclosed |
| CN-1022248-C | Novel 2'-halomethylidene, uridine and guanosine drivatives | MERRELL DOW PHARMA (US) | 1993-09-29 | — | — | CN | disclosed |
| EP-0372268-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| CN-1042715-A | New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl cytidine, uridine and black glycoside derivates | MERRELL DOW PHARMA (US) | 1990-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT14, NUDT1 | LMNA 2089/4885MTOR 3304/4885THRB 4179/4885 |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT1, NUDT14 | LMNA 1937/4885MTOR 3555/4885THRB 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.